Agios
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Agios and other ETFs, options, and stocks.About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology.
CEOBrian M. Goff
CEOBrian M. Goff
Employees488
Employees488
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2007
Founded2007
Employees488
Employees488
AGIO Key Statistics
Market cap2.09B
Market cap2.09B
Price-Earnings ratio3.26
Price-Earnings ratio3.26
Dividend yield—
Dividend yield—
Average volume978.67K
Average volume978.67K
High today$37.91
High today$37.91
Low today$35.91
Low today$35.91
Open price$36.32
Open price$36.32
Volume1.48M
Volume1.48M
52 Week high$62.58
52 Week high$62.58
52 Week low$23.42
52 Week low$23.42
AGIO News
TipRanks 2d
Agios Pharmaceuticals falls -13.3%Agios Pharmaceuticals (AGIO) is down -13.3%, or -$5.40 to $35.21. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock power...
Benzinga 2d
FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded UseOn Thursday, the U.S. Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) goal date for Agios Pharmaceuticals, Inc.’s AGIO su...
TipRanks 2d
Agios Pharmaceuticals provides update on U.S. PDUFA goal date for PYRUKYNDAgios Pharmaceuticals (AGIO) announced that the U.S. Food and Drug Administration, FDA, has extended the Prescription Drug User Fee Act, PDUFA, goal date for th...
Analyst ratings
63%
of 8 ratingsBuy
62.5%
Hold
37.5%
Sell
0%
People also own
Based on the portfolios of people who own AGIO. This list is generated using Robinhood data, and it’s not a recommendation.